ACTRN12614000812695
Terminated
Phase 2
The effect of mesenchymal stem cell injections following arthroscopic microfracture versus microfracture alone on cartilage healing in patients with an isolated knee cartilage defect.
Magellan Stem Cells0 sites40 target enrollmentJuly 31, 2014
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Magellan Stem Cells
- Enrollment
- 40
- Status
- Terminated
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Aged between 18 – 50 (inclusive). As isolated full thickness chondral defects are often traumatic in nature it is likely that this age restriction represents the majority of patients who undergo microfracture.
- •2\.Pre\-operative radiological diagnosis of an isolated full thickness knee cartilage defect of the medial or lateral femoral condyle
- •3\.Planned arthroscopic microfracture/osteoplasty
- •4\.Sufficient English skills to complete the questionnaires required for the study, as well as to understand the instructions given by the study doctors.
- •5\.No plans at the time of enrolment to undergo surgery in the following three months. This criterion is aimed at avoiding co\-interventions that may confound the results of the study. While involvement in the project will not strictly prevent participants from undertaking such interventions if required, we will exclude volunteers who already have such procedures scheduled
Exclusion Criteria
- •1\.Pregnancy (accepted contra\-indication as no safety data on this population).
- •2\.Have other causes of their knee symptoms suspected to be due to serious pathology such as tumour or referral from the hip or lumbar spine. These conditions are not under investigation within the current project;
- •3\.Blood disorder (accepted contra\-indication as no safety data on this population)
- •4\.MRI confirmed displaced meniscial tear.
- •5\.MRI confirmed Grade II\-IV degenerative osteoarthritis
- •6\.History of cancer
- •7\.History of atypical chronic pain syndrome
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress SyndromeModerate to severe SARS-Cov-2 related acute respiratory distress syndromeMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2020-002772-12-FRCHRU NANCY30
Completed
Phase 1
Evaluation of Mesenchymal stem cell therapy effects on the cellular immune response in refractory rheumatoid arthritis patientsRheumatoid arthritis.Diseases of the musculoskeletal system and connective tissueIRCT2015102824760N1Research Chancellor, Mashhad University of Medical Sciences21
Recruiting
Phase 3
Mesenchymal stem cells derived from the placenta and its secretions in the treatment of graft versus host diseaseGraft versus host disease.Graft-versus-host diseaseD89.81IRCT20201108049311N7Tabriz University of Medical Sciences30
Completed
Not Applicable
Effects of cell therapy with mesenchymal stem cells and platelet-rich plasma in the treatment of knee osteoarthritisOsteoarthritis, KneeRBR-2fr526nniversidade Federal de Mato Grosso do Sul
Completed
Not Applicable
Effects of mesenchymal stem cells therapy in peritoneal dialysis patientsChronic kidney disease.Chronic kidney disease, stage 5IRCT2015052415841N2Vice chancellor for research, Tehran University of Medical Sciences10